



## Clinical trial results:

### A Phase 2, Prospective, Randomized, Open-label Study on the Efficacy of Defibrotide Added to Standard of Care Immunoprophylaxis for the Prevention of Acute Graft-versus-Host-Disease in Adult and Pediatric Patients After Allogeneic Hematopoietic Stem Cell Transplant

#### Summary

EudraCT number	2017-003309-16
Trial protocol	DE ES GB IT BE PT AT GR BG PL HR
Global end of trial date	12 May 2020

#### Results information

Result version number	v1 (current)
This version publication date	18 April 2021
First version publication date	18 April 2021

#### Trial information

##### Trial identification

Sponsor protocol code	JZP963-201
-----------------------	------------

##### Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT03339297
WHO universal trial number (UTN)	-
Other trial identifiers	IND: 62,118

Notes:

#### Sponsors

Sponsor organisation name	Jazz Pharmaceuticals Inc.
Sponsor organisation address	3170 Porter Drive, Palo Alto, United States, 94304
Public contact	Director, Clinical Trial Disclosure & Transparency, Jazz Pharmaceuticals, Inc., 215 8709177, ClinicalTrialDisclosure@jazzpharma.com
Scientific contact	Director, Clinical Trial Disclosure & Transparency, Jazz Pharmaceuticals, Inc., 215 8709177, ClinicalTrialDisclosure@jazzpharma.com

Notes:

#### Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	Yes

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	14 January 2021
Is this the analysis of the primary completion data?	Yes
Primary completion date	12 May 2020
Global end of trial reached?	Yes
Global end of trial date	12 May 2020
Was the trial ended prematurely?	No

Notes:

## General information about the trial

Main objective of the trial:

The primary objective of the study is to compare the efficacy of defibrotide added to standard of care immunoprophylaxis vs standard of care (SoC) immunoprophylaxis alone.

Protection of trial subjects:

Written informed consent and/or assent were obtained before any study procedure were performed in the study and the date of the written consent was obtained and documented.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	15 January 2018
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	Spain: 14
Country: Number of subjects enrolled	United Kingdom: 5
Country: Number of subjects enrolled	Austria: 7
Country: Number of subjects enrolled	Belgium: 12
Country: Number of subjects enrolled	Bulgaria: 2
Country: Number of subjects enrolled	France: 17
Country: Number of subjects enrolled	Germany: 14
Country: Number of subjects enrolled	Greece: 3
Country: Number of subjects enrolled	Italy: 9
Country: Number of subjects enrolled	Canada: 1
Country: Number of subjects enrolled	United States: 68
Worldwide total number of subjects	152
EEA total number of subjects	83

Notes:

### Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0

Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	3
Children (2-11 years)	3
Adolescents (12-17 years)	1
Adults (18-64 years)	119
From 65 to 84 years	26
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details: -

### Pre-assignment

Screening details:

Informed consent and/or assent was obtained from participants, parents/legal guardians or representatives.

### Period 1

Period 1 title	Overall trial (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Not blinded

### Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	Defibrotide Prophylaxis

Arm description:

Eligible participants were randomly assigned to receive defibrotide prophylaxis.

Arm type	Experimental
Investigational medicinal product name	Defibrotide Prophylaxis
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Infusion
Routes of administration	Intravenous drip use

Dosage and administration details:

Defibrotide solution was administered intravenously by study site personnel at a dose of 25 mg/kg/day.

<b>Arm title</b>	Standard of Care (SOC)
------------------	------------------------

Arm description:

Eligible participants were randomly assigned to receive SoC immunoprophylaxis alone in a 1:1 ratio.

Arm type	Active comparator
Investigational medicinal product name	SOC
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Infusion
Routes of administration	Intravenous drip use

Dosage and administration details:

Standard of care was administered according to local institutional guidelines, physician preference, and participant need.

<b>Number of subjects in period 1</b>	Defibrotide Prophylaxis	Standard of Care (SOC)
Started	79	73
Completed	56	59
Not completed	23	14
Adverse event, serious fatal	-	2

Physician decision	1	1
Relapse of disease new transplant performed	1	-
Disease relapse	2	-
Hepatic candidosis	1	-
Consent withdrawn by subject	3	3
Patient was not eligible	1	-
Adverse event, non-fatal	1	-
Death	10	7
Early termination, did not proceed to transplant	1	-
Patient relapsed and did not proceed to transplant	-	1
Relapse of hematologic disease	1	-
Problems with donor and diagnosis of early relapse	1	-

## Baseline characteristics

### Reporting groups

Reporting group title	Defibrotide Prophylaxis
-----------------------	-------------------------

Reporting group description:

Eligible participants were randomly assigned to receive defibrotide prophylaxis.

Reporting group title	Standard of Care (SOC)
-----------------------	------------------------

Reporting group description:

Eligible participants were randomly assigned to receive SoC immunoprophylaxis alone in a 1:1 ratio.

Reporting group values	Defibrotide Prophylaxis	Standard of Care (SOC)	Total
Number of subjects	79	73	152
Age categorical Units: Subjects			
Age continuous Units: years arithmetic mean standard deviation	50.54 ± 16.952	51.09 ± 16.621	-
Gender categorical Units: Subjects			
Female	38	37	75
Male	41	36	77

## End points

### End points reporting groups

Reporting group title	Defibrotide Prophylaxis
Reporting group description:	
Eligible participants were randomly assigned to receive defibrotide prophylaxis.	
Reporting group title	Standard of Care (SOC)
Reporting group description:	
Eligible participants were randomly assigned to receive SoC immunoprophylaxis alone in a 1:1 ratio.	

### Primary: Percentage of Participants with Cumulative Incidence of Grade B to D Acute Graft Versus Host Disease (aGvHD) by Day +100 post-Hematopoietic Stem Cell Transplant (HSCT)

End point title	Percentage of Participants with Cumulative Incidence of Grade B to D Acute Graft Versus Host Disease (aGvHD) by Day +100 post-Hematopoietic Stem Cell Transplant (HSCT)
End point description:	
End point type	Primary
End point timeframe:	
Baseline through Day +100 post-HSCT	

End point values	Defibrotide Prophylaxis	Standard of Care (SOC)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	79	73		
Units: participants				
number (not applicable)	38.4	47.1		

### Statistical analyses

Statistical analysis title	P-value from Stratified Gray's Test
Statistical analysis description:	
The treatment comparison on the cumulative incidence of Grade B-D aGvHD over time was conducted using a stratified Gray's test. The resulting p-value was not applicable to any specific timepoint, but rather the whole duration of the study.	
Comparison groups	Defibrotide Prophylaxis v Standard of Care (SOC)
Number of subjects included in analysis	152
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.6656
Method	t-test, 2-sided

---

**Secondary: Percentage of Participants with Cumulative Incidence of Grade B to D aGvHD by Day +180 post-HSCT**

---

End point title	Percentage of Participants with Cumulative Incidence of Grade B to D aGvHD by Day +180 post-HSCT
-----------------	--

---

End point description:

End point type	Secondary
----------------	-----------

---

End point timeframe:

Day +180 post-HSCT

---

End point values	Defibrotide Prophylaxis	Standard of Care (SOC)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	79	73		
Units: participants				
number (not applicable)	50.6	51.6		

---

**Statistical analyses**

---

No statistical analyses for this end point



## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

Adverse Events (AEs) were reported from the time of signed informed consent form (ICF) and were recorded up to Day +63 post-HSCT for subjects who underwent HSCT, whereas for subjects who did not undergo HSCT, 70 days after baseline.

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
Dictionary version	21.1

### Reporting groups

Reporting group title	defibrotide prophylaxis
-----------------------	-------------------------

Reporting group description: -

Reporting group title	Standard of Care (SOC)
-----------------------	------------------------

Reporting group description: -

Serious adverse events	defibrotide prophylaxis	Standard of Care (SOC)	
Total subjects affected by serious adverse events			
subjects affected / exposed	31 / 74 (41.89%)	31 / 70 (44.29%)	
number of deaths (all causes)	10	9	
number of deaths resulting from adverse events	5	3	
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Acute lymphocytic leukaemia recurrent			
subjects affected / exposed	0 / 74 (0.00%)	1 / 70 (1.43%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Acute myeloid leukaemia recurrent			
subjects affected / exposed	0 / 74 (0.00%)	1 / 70 (1.43%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Epstein-Barr virus associated lymphoproliferative disorder			
subjects affected / exposed	0 / 74 (0.00%)	1 / 70 (1.43%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular disorders			
Obstructive shock			

subjects affected / exposed	0 / 74 (0.00%)	1 / 70 (1.43%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Shock			
subjects affected / exposed	0 / 74 (0.00%)	1 / 70 (1.43%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Venoocclusive disease			
subjects affected / exposed	1 / 74 (1.35%)	1 / 70 (1.43%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 0	
General disorders and administration site conditions			
General physical health deterioration			
subjects affected / exposed	0 / 74 (0.00%)	1 / 70 (1.43%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mucosal haemorrhage			
subjects affected / exposed	1 / 74 (1.35%)	0 / 70 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Mucosal inflammation			
subjects affected / exposed	1 / 74 (1.35%)	0 / 70 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Multiple organ dysfunction syndrome			
subjects affected / exposed	1 / 74 (1.35%)	1 / 70 (1.43%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Pyrexia			
subjects affected / exposed	1 / 74 (1.35%)	0 / 70 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Immune system disorders			

Acute graft versus host disease subjects affected / exposed	4 / 74 (5.41%)	1 / 70 (1.43%)	
occurrences causally related to treatment / all	0 / 5	0 / 1	
deaths causally related to treatment / all	0 / 2	0 / 0	
Acute graft versus host disease in skin			
subjects affected / exposed	1 / 74 (1.35%)	4 / 70 (5.71%)	
occurrences causally related to treatment / all	0 / 1	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
Graft versus host disease			
subjects affected / exposed	0 / 74 (0.00%)	1 / 70 (1.43%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Graft versus host disease in liver			
subjects affected / exposed	0 / 74 (0.00%)	1 / 70 (1.43%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Acute graft versus host disease in intestine			
subjects affected / exposed	2 / 74 (2.70%)	1 / 70 (1.43%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory, thoracic and mediastinal disorders			
Acute respiratory failure			
subjects affected / exposed	1 / 74 (1.35%)	1 / 70 (1.43%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dyspnoea			
subjects affected / exposed	3 / 74 (4.05%)	0 / 70 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Epistaxis			

subjects affected / exposed	1 / 74 (1.35%)	0 / 70 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lung disorder			
subjects affected / exposed	0 / 74 (0.00%)	1 / 70 (1.43%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Pharyngeal inflammation			
subjects affected / exposed	0 / 74 (0.00%)	1 / 70 (1.43%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pleural effusion			
subjects affected / exposed	0 / 74 (0.00%)	1 / 70 (1.43%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary embolism			
subjects affected / exposed	0 / 74 (0.00%)	1 / 70 (1.43%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pulmonary oedema			
subjects affected / exposed	0 / 74 (0.00%)	1 / 70 (1.43%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory failure			
subjects affected / exposed	1 / 74 (1.35%)	1 / 70 (1.43%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 0	
Investigations			
Blood potassium decreased			
subjects affected / exposed	0 / 74 (0.00%)	1 / 70 (1.43%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ejection fraction decreased			

subjects affected / exposed	0 / 74 (0.00%)	1 / 70 (1.43%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Injury, poisoning and procedural complications			
Toxicity to various agents			
subjects affected / exposed	0 / 74 (0.00%)	1 / 70 (1.43%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Transfusion reaction			
subjects affected / exposed	0 / 74 (0.00%)	1 / 70 (1.43%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac disorders			
Atrial flutter			
subjects affected / exposed	1 / 74 (1.35%)	0 / 70 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac tamponade			
subjects affected / exposed	0 / 74 (0.00%)	1 / 70 (1.43%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardio-respiratory arrest			
subjects affected / exposed	1 / 74 (1.35%)	0 / 70 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiogenic shock			
subjects affected / exposed	1 / 74 (1.35%)	1 / 70 (1.43%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sinus tachycardia			
subjects affected / exposed	1 / 74 (1.35%)	0 / 70 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Stress cardiomyopathy			
subjects affected / exposed	0 / 74 (0.00%)	1 / 70 (1.43%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Supraventricular tachycardia			
subjects affected / exposed	1 / 74 (1.35%)	0 / 70 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nervous system disorders			
Cognitive disorder			
subjects affected / exposed	1 / 74 (1.35%)	0 / 70 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypertensive encephalopathy			
subjects affected / exposed	0 / 74 (0.00%)	1 / 70 (1.43%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Syncope			
subjects affected / exposed	1 / 74 (1.35%)	0 / 70 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood and lymphatic system disorders			
Eosinophilia			
subjects affected / exposed	1 / 74 (1.35%)	0 / 70 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Evans syndrome			
subjects affected / exposed	1 / 74 (1.35%)	0 / 70 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Febrile neutropenia			
subjects affected / exposed	1 / 74 (1.35%)	0 / 70 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Thrombotic microangiopathy subjects affected / exposed	1 / 74 (1.35%)	0 / 70 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal disorders			
Abdominal pain subjects affected / exposed	1 / 74 (1.35%)	0 / 70 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Acute abdomen subjects affected / exposed	0 / 74 (0.00%)	1 / 70 (1.43%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Constipation subjects affected / exposed	1 / 74 (1.35%)	0 / 70 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diarrhoea subjects affected / exposed	3 / 74 (4.05%)	2 / 70 (2.86%)	
occurrences causally related to treatment / all	0 / 3	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Intestinal haemorrhage subjects affected / exposed	0 / 74 (0.00%)	1 / 70 (1.43%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Nausea subjects affected / exposed	2 / 74 (2.70%)	1 / 70 (1.43%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Oesophagitis subjects affected / exposed	1 / 74 (1.35%)	0 / 70 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Stomatitis			

subjects affected / exposed	0 / 74 (0.00%)	1 / 70 (1.43%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Upper gastrointestinal haemorrhage			
subjects affected / exposed	1 / 74 (1.35%)	0 / 70 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vomiting			
subjects affected / exposed	2 / 74 (2.70%)	1 / 70 (1.43%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hepatobiliary disorders			
Venoocclusive liver disease			
subjects affected / exposed	0 / 74 (0.00%)	2 / 70 (2.86%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Skin and subcutaneous tissue disorders			
Rash vesicular			
subjects affected / exposed	1 / 74 (1.35%)	0 / 70 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Toxic skin eruption			
subjects affected / exposed	1 / 74 (1.35%)	0 / 70 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Renal and urinary disorders			
Acute kidney injury			
subjects affected / exposed	3 / 74 (4.05%)	2 / 70 (2.86%)	
occurrences causally related to treatment / all	0 / 3	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cystitis haemorrhagic			
subjects affected / exposed	1 / 74 (1.35%)	1 / 70 (1.43%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	



Infections and infestations Arthritis bacterial subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	1 / 74 (1.35%) 0 / 1 0 / 0	0 / 70 (0.00%) 0 / 0 0 / 0	
Bacterial sepsis subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	1 / 74 (1.35%) 0 / 1 0 / 1	0 / 70 (0.00%) 0 / 0 0 / 0	
Bronchitis subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 74 (0.00%) 0 / 0 0 / 0	1 / 70 (1.43%) 0 / 1 0 / 0	
Clostridium difficile colitis subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	1 / 74 (1.35%) 0 / 1 0 / 0	0 / 70 (0.00%) 0 / 0 0 / 0	
Cystitis viral subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	1 / 74 (1.35%) 0 / 1 0 / 0	0 / 70 (0.00%) 0 / 0 0 / 0	
Cytomegalovirus infection subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 74 (0.00%) 0 / 0 0 / 0	1 / 70 (1.43%) 0 / 1 0 / 0	
Cytomegalovirus viraemia subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	0 / 74 (0.00%) 0 / 0 0 / 0	1 / 70 (1.43%) 0 / 1 0 / 0	
Device related infection subjects affected / exposed occurrences causally related to treatment / all deaths causally related to treatment / all	1 / 74 (1.35%) 0 / 1 0 / 0	0 / 70 (0.00%) 0 / 0 0 / 0	
Epstein-Barr viraemia			

subjects affected / exposed	1 / 74 (1.35%)	0 / 70 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Epstein-Barr virus infection			
subjects affected / exposed	1 / 74 (1.35%)	0 / 70 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Fungaemia			
subjects affected / exposed	0 / 74 (0.00%)	1 / 70 (1.43%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory tract infection			
subjects affected / exposed	0 / 74 (0.00%)	1 / 70 (1.43%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sepsis			
subjects affected / exposed	0 / 74 (0.00%)	2 / 70 (2.86%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Septic shock			
subjects affected / exposed	0 / 74 (0.00%)	2 / 70 (2.86%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Serratia infection			
subjects affected / exposed	0 / 74 (0.00%)	1 / 70 (1.43%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Staphylococcal bacteraemia			
subjects affected / exposed	0 / 74 (0.00%)	1 / 70 (1.43%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urinary tract infection			

subjects affected / exposed	0 / 74 (0.00%)	1 / 70 (1.43%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Urinary tract infection bacterial			
subjects affected / exposed	0 / 74 (0.00%)	1 / 70 (1.43%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular device infection			
subjects affected / exposed	0 / 74 (0.00%)	1 / 70 (1.43%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metabolism and nutrition disorders			
Decreased appetite			
subjects affected / exposed	2 / 74 (2.70%)	1 / 70 (1.43%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dehydration			
subjects affected / exposed	0 / 74 (0.00%)	1 / 70 (1.43%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Failure to thrive			
subjects affected / exposed	1 / 74 (1.35%)	0 / 70 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyperkalaemia			
subjects affected / exposed	1 / 74 (1.35%)	0 / 70 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypokalaemia			
subjects affected / exposed	0 / 74 (0.00%)	1 / 70 (1.43%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypovolaemia			

subjects affected / exposed	1 / 74 (1.35%)	0 / 70 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 5 %

<b>Non-serious adverse events</b>	defibrotide prophylaxis	Standard of Care (SOC)	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	74 / 74 (100.00%)	70 / 70 (100.00%)	
Vascular disorders			
Flushing			
subjects affected / exposed	4 / 74 (5.41%)	4 / 70 (5.71%)	
occurrences (all)	6	4	
Hypertension			
subjects affected / exposed	25 / 74 (33.78%)	29 / 70 (41.43%)	
occurrences (all)	40	32	
Hypotension			
subjects affected / exposed	13 / 74 (17.57%)	11 / 70 (15.71%)	
occurrences (all)	16	14	
Orthostatic hypotension			
subjects affected / exposed	6 / 74 (8.11%)	3 / 70 (4.29%)	
occurrences (all)	6	3	
General disorders and administration site conditions			
Asthenia			
subjects affected / exposed	9 / 74 (12.16%)	6 / 70 (8.57%)	
occurrences (all)	12	6	
Catheter site pain			
subjects affected / exposed	8 / 74 (10.81%)	9 / 70 (12.86%)	
occurrences (all)	10	10	
Chills			
subjects affected / exposed	7 / 74 (9.46%)	6 / 70 (8.57%)	
occurrences (all)	8	7	
Fatigue			
subjects affected / exposed	25 / 74 (33.78%)	25 / 70 (35.71%)	
occurrences (all)	32	27	

Mucosal inflammation subjects affected / exposed occurrences (all)	10 / 74 (13.51%) 11	17 / 70 (24.29%) 24	
Oedema peripheral subjects affected / exposed occurrences (all)	19 / 74 (25.68%) 125	21 / 70 (30.00%) 24	
Pain subjects affected / exposed occurrences (all)	5 / 74 (6.76%) 7	6 / 70 (8.57%) 7	
Pyrexia subjects affected / exposed occurrences (all)	28 / 74 (37.84%) 38	24 / 70 (34.29%) 34	
Immune system disorders Graft versus host disease in skin subjects affected / exposed occurrences (all)	4 / 74 (5.41%) 4	2 / 70 (2.86%) 2	
Respiratory, thoracic and mediastinal disorders Cough subjects affected / exposed occurrences (all)	17 / 74 (22.97%) 20	16 / 70 (22.86%) 20	
Dyspnoea subjects affected / exposed occurrences (all)	8 / 74 (10.81%) 12	12 / 70 (17.14%) 19	
Epistaxis subjects affected / exposed occurrences (all)	12 / 74 (16.22%) 13	11 / 70 (15.71%) 13	
Hiccups subjects affected / exposed occurrences (all)	5 / 74 (6.76%) 5	3 / 70 (4.29%) 3	
Hypoxia subjects affected / exposed occurrences (all)	4 / 74 (5.41%) 4	3 / 70 (4.29%) 7	
Nasal congestion subjects affected / exposed occurrences (all)	4 / 74 (5.41%) 6	1 / 70 (1.43%) 1	
Oropharyngeal pain			

subjects affected / exposed occurrences (all)	9 / 74 (12.16%) 9	12 / 70 (17.14%) 14	
Pleural effusion subjects affected / exposed occurrences (all)	4 / 74 (5.41%) 6	3 / 70 (4.29%) 4	
Productive cough subjects affected / exposed occurrences (all)	5 / 74 (6.76%) 6	0 / 70 (0.00%) 0	
Rales subjects affected / exposed occurrences (all)	4 / 74 (5.41%) 4	2 / 70 (2.86%) 4	
Rhinitis allergic subjects affected / exposed occurrences (all)	2 / 74 (2.70%) 2	4 / 70 (5.71%) 4	
Rhinorrhoea subjects affected / exposed occurrences (all)	6 / 74 (8.11%) 7	9 / 70 (12.86%) 9	
Tachypnoea subjects affected / exposed occurrences (all)	4 / 74 (5.41%) 5	2 / 70 (2.86%) 2	
Psychiatric disorders			
Agitation subjects affected / exposed occurrences (all)	5 / 74 (6.76%) 5	3 / 70 (4.29%) 3	
Anxiety subjects affected / exposed occurrences (all)	11 / 74 (14.86%) 11	9 / 70 (12.86%) 9	
Confusional state subjects affected / exposed occurrences (all)	5 / 74 (6.76%) 6	3 / 70 (4.29%) 3	
Delirium subjects affected / exposed occurrences (all)	4 / 74 (5.41%) 5	2 / 70 (2.86%) 2	
Depression subjects affected / exposed occurrences (all)	7 / 74 (9.46%) 7	2 / 70 (2.86%) 2	

Insomnia			
subjects affected / exposed	22 / 74 (29.73%)	16 / 70 (22.86%)	
occurrences (all)	24	18	
Investigations			
Alanine aminotransferase increased			
subjects affected / exposed	3 / 74 (4.05%)	7 / 70 (10.00%)	
occurrences (all)	7	10	
Aspartate aminotransferase increased			
subjects affected / exposed	2 / 74 (2.70%)	5 / 70 (7.14%)	
occurrences (all)	2	6	
Bacterial test positive			
subjects affected / exposed	4 / 74 (5.41%)	3 / 70 (4.29%)	
occurrences (all)	5	6	
Blood bilirubin increased			
subjects affected / exposed	3 / 74 (4.05%)	5 / 70 (7.14%)	
occurrences (all)	5	13	
Blood creatinine increased			
subjects affected / exposed	12 / 74 (16.22%)	6 / 70 (8.57%)	
occurrences (all)	14	6	
Blood magnesium decreased			
subjects affected / exposed	1 / 74 (1.35%)	4 / 70 (5.71%)	
occurrences (all)	1	6	
C-reactive protein increased			
subjects affected / exposed	4 / 74 (5.41%)	5 / 70 (7.14%)	
occurrences (all)	4	6	
Epstein-Barr virus test positive			
subjects affected / exposed	4 / 74 (5.41%)	2 / 70 (2.86%)	
occurrences (all)	4	2	
Neutrophil count decreased			
subjects affected / exposed	8 / 74 (10.81%)	11 / 70 (15.71%)	
occurrences (all)	20	23	
Platelet count decreased			
subjects affected / exposed	19 / 74 (25.68%)	21 / 70 (30.00%)	
occurrences (all)	54	56	
Transaminases increased			

subjects affected / exposed occurrences (all)	4 / 74 (5.41%) 4	6 / 70 (8.57%) 7	
Weight decreased subjects affected / exposed occurrences (all)	3 / 74 (4.05%) 4	4 / 70 (5.71%) 5	
White blood cell count decreased subjects affected / exposed occurrences (all)	8 / 74 (10.81%) 15	6 / 70 (8.57%) 17	
Injury, poisoning and procedural complications			
Fall subjects affected / exposed occurrences (all)	5 / 74 (6.76%) 5	2 / 70 (2.86%) 2	
Infusion related reaction subjects affected / exposed occurrences (all)	4 / 74 (5.41%) 4	6 / 70 (8.57%) 6	
Limb injury subjects affected / exposed occurrences (all)	4 / 74 (5.41%) 5	1 / 70 (1.43%) 1	
Skin abrasion subjects affected / exposed occurrences (all)	1 / 74 (1.35%) 1	4 / 70 (5.71%) 5	
Cardiac disorders			
Sinus tachycardia subjects affected / exposed occurrences (all)	9 / 74 (12.16%) 10	8 / 70 (11.43%) 12	
Nervous system disorders			
Dizziness subjects affected / exposed occurrences (all)	10 / 74 (13.51%) 11	8 / 70 (11.43%) 12	
Dysgeusia subjects affected / exposed occurrences (all)	10 / 74 (13.51%) 12	9 / 70 (12.86%) 9	
Headache subjects affected / exposed occurrences (all)	31 / 74 (41.89%) 40	23 / 70 (32.86%) 36	
Restless legs syndrome			



subjects affected / exposed occurrences (all)	5 / 74 (6.76%) 5	1 / 70 (1.43%) 1	
Somnolence subjects affected / exposed occurrences (all)	5 / 74 (6.76%) 7	2 / 70 (2.86%) 2	
Tremor subjects affected / exposed occurrences (all)	10 / 74 (13.51%) 11	9 / 70 (12.86%) 10	
Blood and lymphatic system disorders			
Anaemia subjects affected / exposed occurrences (all)	27 / 74 (36.49%) 49	30 / 70 (42.86%) 60	
Febrile neutropenia subjects affected / exposed occurrences (all)	30 / 74 (40.54%) 32	20 / 70 (28.57%) 20	
Leukopenia subjects affected / exposed occurrences (all)	9 / 74 (12.16%) 18	6 / 70 (8.57%) 12	
Neutropenia subjects affected / exposed occurrences (all)	12 / 74 (16.22%) 28	17 / 70 (24.29%) 28	
Thrombocytopenia subjects affected / exposed occurrences (all)	19 / 74 (25.68%) 36	19 / 70 (27.14%) 41	
Eye disorders			
Dry eye subjects affected / exposed occurrences (all)	15 / 74 (20.27%) 15	6 / 70 (8.57%) 7	
Eye swelling subjects affected / exposed occurrences (all)	0 / 74 (0.00%) 0	4 / 70 (5.71%) 4	
Gastrointestinal disorders			
Abdominal distension subjects affected / exposed occurrences (all)	8 / 74 (10.81%) 13	5 / 70 (7.14%) 6	
Abdominal pain			

subjects affected / exposed	13 / 74 (17.57%)	22 / 70 (31.43%)
occurrences (all)	18	24
Abdominal pain lower		
subjects affected / exposed	4 / 74 (5.41%)	0 / 70 (0.00%)
occurrences (all)	4	0
Abdominal pain upper		
subjects affected / exposed	5 / 74 (6.76%)	9 / 70 (12.86%)
occurrences (all)	7	15
Constipation		
subjects affected / exposed	28 / 74 (37.84%)	29 / 70 (41.43%)
occurrences (all)	34	37
Diarrhoea		
subjects affected / exposed	47 / 74 (63.51%)	53 / 70 (75.71%)
occurrences (all)	71	77
Dry mouth		
subjects affected / exposed	7 / 74 (9.46%)	6 / 70 (8.57%)
occurrences (all)	8	6
Dyspepsia		
subjects affected / exposed	4 / 74 (5.41%)	11 / 70 (15.71%)
occurrences (all)	4	13
Dysphagia		
subjects affected / exposed	5 / 74 (6.76%)	3 / 70 (4.29%)
occurrences (all)	6	7
Flatulence		
subjects affected / exposed	4 / 74 (5.41%)	3 / 70 (4.29%)
occurrences (all)	4	3
Haemorrhoids		
subjects affected / exposed	6 / 74 (8.11%)	6 / 70 (8.57%)
occurrences (all)	10	6
Mouth ulceration		
subjects affected / exposed	4 / 74 (5.41%)	1 / 70 (1.43%)
occurrences (all)	5	1
Nausea		
subjects affected / exposed	56 / 74 (75.68%)	49 / 70 (70.00%)
occurrences (all)	89	70
Odynophagia		

subjects affected / exposed	7 / 74 (9.46%)	3 / 70 (4.29%)	
occurrences (all)	9	3	
Oesophagitis			
subjects affected / exposed	5 / 74 (6.76%)	0 / 70 (0.00%)	
occurrences (all)	7	0	
Stomatitis			
subjects affected / exposed	42 / 74 (56.76%)	36 / 70 (51.43%)	
occurrences (all)	68	69	
Vomiting			
subjects affected / exposed	39 / 74 (52.70%)	38 / 70 (54.29%)	
occurrences (all)	66	62	
Skin and subcutaneous tissue disorders			
Alopecia			
subjects affected / exposed	5 / 74 (6.76%)	3 / 70 (4.29%)	
occurrences (all)	5	3	
Dry skin			
subjects affected / exposed	7 / 74 (9.46%)	8 / 70 (11.43%)	
occurrences (all)	7	8	
Erythema			
subjects affected / exposed	13 / 74 (17.57%)	13 / 70 (18.57%)	
occurrences (all)	18	19	
Hyperhidrosis			
subjects affected / exposed	4 / 74 (5.41%)	1 / 70 (1.43%)	
occurrences (all)	4	1	
Petechiae			
subjects affected / exposed	2 / 74 (2.70%)	4 / 70 (5.71%)	
occurrences (all)	2	4	
Pruritus			
subjects affected / exposed	11 / 74 (14.86%)	13 / 70 (18.57%)	
occurrences (all)	13	15	
Pruritus generalised			
subjects affected / exposed	4 / 74 (5.41%)	5 / 70 (7.14%)	
occurrences (all)	5	6	
Rash			
subjects affected / exposed	17 / 74 (22.97%)	19 / 70 (27.14%)	
occurrences (all)	31	27	

Rash maculo-papular subjects affected / exposed occurrences (all)	7 / 74 (9.46%) 10	7 / 70 (10.00%) 7	
Skin hyperpigmentation subjects affected / exposed occurrences (all)	2 / 74 (2.70%) 2	5 / 70 (7.14%) 5	
Renal and urinary disorders			
Acute kidney injury subjects affected / exposed occurrences (all)	17 / 74 (22.97%) 22	16 / 70 (22.86%) 21	
Cystitis haemorrhagic subjects affected / exposed occurrences (all)	2 / 74 (2.70%) 2	4 / 70 (5.71%) 6	
Dysuria subjects affected / exposed occurrences (all)	6 / 74 (8.11%) 7	5 / 70 (7.14%) 6	
Haematuria subjects affected / exposed occurrences (all)	3 / 74 (4.05%) 4	4 / 70 (5.71%) 5	
Pollakiuria subjects affected / exposed occurrences (all)	4 / 74 (5.41%) 6	4 / 70 (5.71%) 4	
Urinary retention subjects affected / exposed occurrences (all)	4 / 74 (5.41%) 4	0 / 70 (0.00%) 0	
Musculoskeletal and connective tissue disorders			
Arthralgia subjects affected / exposed occurrences (all)	10 / 74 (13.51%) 11	6 / 70 (8.57%) 8	
Back pain subjects affected / exposed occurrences (all)	8 / 74 (10.81%) 9	12 / 70 (17.14%) 13	
Bone pain subjects affected / exposed occurrences (all)	3 / 74 (4.05%) 4	4 / 70 (5.71%) 4	
Musculoskeletal pain			

subjects affected / exposed occurrences (all)	6 / 74 (8.11%) 8	1 / 70 (1.43%) 1	
Myalgia subjects affected / exposed occurrences (all)	6 / 74 (8.11%) 7	2 / 70 (2.86%) 2	
Neck pain subjects affected / exposed occurrences (all)	5 / 74 (6.76%) 6	3 / 70 (4.29%) 3	
Pain in extremity subjects affected / exposed occurrences (all)	5 / 74 (6.76%) 7	3 / 70 (4.29%) 3	
Infections and infestations Clostridium difficile colitis subjects affected / exposed occurrences (all)	3 / 74 (4.05%) 3	4 / 70 (5.71%) 4	
Cytomegalovirus infection subjects affected / exposed occurrences (all)	11 / 74 (14.86%) 12	14 / 70 (20.00%) 15	
Oral candidiasis subjects affected / exposed occurrences (all)	0 / 74 (0.00%) 0	6 / 70 (8.57%) 7	
Urinary tract infection subjects affected / exposed occurrences (all)	3 / 74 (4.05%) 3	6 / 70 (8.57%) 7	
Metabolism and nutrition disorders Decreased appetite subjects affected / exposed occurrences (all)	30 / 74 (40.54%) 39	30 / 70 (42.86%) 37	
Dehydration subjects affected / exposed occurrences (all)	4 / 74 (5.41%) 4	5 / 70 (7.14%) 5	
Fluid overload subjects affected / exposed occurrences (all)	5 / 74 (6.76%) 5	5 / 70 (7.14%) 6	
Fluid retention			

subjects affected / exposed	6 / 74 (8.11%)	4 / 70 (5.71%)
occurrences (all)	9	10
Hyperglycaemia		
subjects affected / exposed	12 / 74 (16.22%)	9 / 70 (12.86%)
occurrences (all)	24	17
Hyperkalaemia		
subjects affected / exposed	5 / 74 (6.76%)	8 / 70 (11.43%)
occurrences (all)	5	12
Hypernatraemia		
subjects affected / exposed	2 / 74 (2.70%)	5 / 70 (7.14%)
occurrences (all)	6	5
Hypoalbuminaemia		
subjects affected / exposed	8 / 74 (10.81%)	2 / 70 (2.86%)
occurrences (all)	9	3
Hypocalcaemia		
subjects affected / exposed	3 / 74 (4.05%)	5 / 70 (7.14%)
occurrences (all)	3	9
Hypokalaemia		
subjects affected / exposed	24 / 74 (32.43%)	27 / 70 (38.57%)
occurrences (all)	36	44
Hypomagnesaemia		
subjects affected / exposed	30 / 74 (40.54%)	35 / 70 (50.00%)
occurrences (all)	52	59
Hyponatraemia		
subjects affected / exposed	8 / 74 (10.81%)	5 / 70 (7.14%)
occurrences (all)	9	6
Hypophagia		
subjects affected / exposed	1 / 74 (1.35%)	5 / 70 (7.14%)
occurrences (all)	1	6
Hypophosphataemia		
subjects affected / exposed	5 / 74 (6.76%)	11 / 70 (15.71%)
occurrences (all)	9	25
Malnutrition		
subjects affected / exposed	4 / 74 (5.41%)	6 / 70 (8.57%)
occurrences (all)	4	6



## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
19 June 2018	<p>Section 4.1 Inclusion criteria: #1 updated to remove upper limit of age &lt;75 years for inclusion. #8 to remove requirement of negative serum pregnancy tests at Days +28 and +63 post-HSCT. Section 4.2 Exclusion criteria: #3 updated to clarify that use of heparin or other anticoagulants for routine central venous line management, and intermittent dialysis or ultrafiltration as well as fibrinolytic instillation for central venous line occlusion will be allowed. #5 updated to exclude patients receiving or planning to receive other investigational therapy #11 updated to add description on hypersensitivity to any agent in patient's planned immunoprophylaxis regimen. Added #12 on patient having any contraindications to agent(s) within immunoprophylaxis regimens allowed by protocol order to address contraindications, special precautions, and warnings for medicinal products used as standard of care (SoC).</p> <p>Section 5.1.2 &amp; 5.2.2 updated to add a clarification to a reference SmPC or approved label for warnings and precautions associated with reference therapy. Section 5.2.1 to provide info on administration setting and guidance on defibrotide dosing window.</p> <p>Section 5.7.5 to remove prohibition against all investigational therapies. Section 6.8 to clarify that clinically significant laboratory values are to be reported as adverse events only if they are clinically significant as assessed by the investigator. Patients who do not receive HSCT, AEs will be collected up to 70 days after baseline.</p> <p>Section 6.8.1.7 Pregnancy has been harmonised with language in Section 6.9.1 pregnancy is a reason why study drug must be permanently discontinued. Section 6.9.1 to differentiate reasons for discontinuation of a patient from the study and discontinuation from the study drug, and to differentiate between reason that 'must' and that 'may' lead to an early termination.</p> <p>Section 7.1 &amp; 7.3 to clarify that bone marrow aspirate and biopsy are required for assessment of disease relapse.</p>

Notes:

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

None reported